医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Japanese Regulatory Agency Licenses Certara’s Phoenix and Simcyp Software to Support Model-based Drug Development

2015年02月26日 PM10:00
このエントリーをはてなブックマークに追加


 

PRINCETON, N.J.

Certara®, the global biosimulation technology-enabled drug development and drug safety consulting company, today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) is equipping its pharmacometrics team with Certara’s Phoenix® biosimulation solutions and its Simcyp™ Population-based Simulator. PMDA joins FDA and several other global regulatory agencies in increasing its reliance on biosimulation for investigational new drug and new drug approval reviews.

“Biosimulation is now consistently relied upon by regulatory agencies’ pharmacometrics teams in pre-clinical, clinical and post-approval drug development decisions,” said Certara CEO Edmundo Muniz, M.D., Ph.D. “Furthermore, a paper and survey from the International Consortium for Innovation and Quality in Pharmaceutical Development published by the American Association of Pharmaceutical Scientists last month stated that Phoenix was used by 100 percent of the 22 leading pharmaceutical companies surveyed, and 86 percent of them were using Simcyp. These percentages placed Certara’s offerings as the #1 and #2 ranked biosimulation solutions. We are proud to be working with PMDA, as it advances the use of these innovative modeling approaches from regulatory science to regulatory approval.”

PMDA is using PPK (population pharmacokinetic), PK/PD (pharmacokinetic/pharmacodynamic), and other modeling and biosimulation approaches for dosage, dose regimen and dose adjustment for special populations, including pediatrics. In addition, PKS Online will provide the technical infrastructure necessary to securely store and manage PK and PD study data, and the associated pharmacometric analyses, in a regulatory-compliant environment.

Certara’s Simcyp Simulator is the pharmaceutical industry’s most sophisticated platform for the prediction of drug-drug interactions, assisting in dose selection, and informing clinical decisions related to product labeling. Simcyp whole body simulation methodology can predict the pharmacokinetics of drug compounds and proteins based on in vitro data. The simulator includes a unique set of genetic, physiological and epidemiological databases that facilitate the simulation of virtual populations from around the globe.

In addition to PMDA, all leading Japanese pharmaceutical companies have integrated both the Phoenix and Simcyp biosimulation solutions into their drug development workflow.

About Certara

Certara is the global biosimulation technology-enabled drug development and drug safety consulting company. Its customers include hundreds of biopharmaceutical companies around the globe, together with several regulatory agencies. Certara’s solutions, which span the discovery, preclinical and clinical stages of drug development, enable data-driven decisions, leading to more precisely designed trials with a reduced risk of failure and improved subject safety. For more information, visit www.certara.com.

CONTACT

Certara Contact:
Teresa A. Bradford, 919-852-4644
Senior
Director, Marketing
teresa.bradford@certara.com
or
Media
Contact:

Lisa Osborne, 206-992-5245
Rana Healthcare
Solutions
lisa@ranahealth.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease